Obstructive sleep apnoea (OSA) is a usual sleep disorder affecting millions of
people worldwide. This condition is characteristic of recurrent episodes of upper
airway obstruction during sleep. This condition results in intermittent hypoxia
and also sleep fragmentation. Due to OSA, there is a range of adverse health
outcomes, including chronic fatigue, daytime sleepiness, depression, and an
increased cardiovascular risk. Cardiovascular diseases (CVD) include
hypertension, coronary artery disease (CAD), myocardial infarction, stroke,
arrhythmias, and other diseases. This syndrome can be potentially lifethreatening.
The pathophysiological mechanisms linking OSA to CVD are
multifactorial, including but not limited to increased sympathetic activity,
chronic inflammation, oxidative stress, and endothelial dysfunction, which is a
part of the discussion in our review. The processes mentioned contribute to the
development and progression of atherosclerosis, coronary heart disease, and
heart failure. In addition, this review examines the efficacy of different
therapeutic approaches for treating sleep apnoea. A considerable body of
evidence from many studies indicates that the treatment of OSA has a two-fold
effect: it alleviates the severity of apnoea but also reduces the risk of
cardiovascular disease. Continuous positive airway pressure (CPAP) is the most
important aspect of treating sleep apnoea, particularly in cases of moderate to
severe severity. CPAP is an effective method for reducing disease severity,
lowering blood pressure, and improving sleep quality. Therefore, the treatment
of OSA is crucial in the prevention and treatment of cardiovascular diseases.
Keywords: Obstructive sleep apnoea, cardiovascular disease, heart failure,
inflammation
